Adult human mesenchymal stem cells delivered via intra-articular injection to the knee following partial medial meniscectomy: a randomized, double-blind, controlled study.

@article{Vangsness2014AdultHM,
  title={Adult human mesenchymal stem cells delivered via intra-articular injection to the knee following partial medial meniscectomy: a randomized, double-blind, controlled study.},
  author={C. Thomas Vangsness and Jack Farr and Joel L. Boyd and David T Dellaero and C Randal Mills and Michelle LeRoux-Williams},
  journal={The Journal of bone and joint surgery. American volume},
  year={2014},
  volume={96 2},
  pages={
          90-8
        }
}
BACKGROUND There are limited treatment options for tissue restoration and the prevention of degenerative changes in the knee. [] Key MethodMETHODS A total of fifty-five patients at seven institutions underwent a partial medial meniscectomy. A single superolateral knee injection was given within seven to ten days after the meniscectomy. Patients were randomized to one of three treatment groups: Group A, in which patients received an injection of 50 × 10⁶ allogeneic mesenchymal stem cells; Group B, 150 × 10…
View on PubMed
cartilagerestoration.org
356 Citations
Highly Influential Citations
18
Background Citations
90
Methods Citations
18
Results Citations
20

Figures and Tables from this paper

356 Citations

Intra-articular Implantation of Mesenchymal Stem Cells, Part 2

Limited results from animal studies suggest that there is some potential for intra-articular injection of MSCs for the regeneration of meniscal tissue, but further studies are necessary to determine the quality of regenerated meniscus tissue through histological and biomechanical testing.

Intra-articular Implantation of Mesenchymal Stem Cells, Part 1

The purpose of this review is to highlight the findings in the presently available literature on the use of intra-articular implantation of MSCs postmeniscectomy and to offer suggestions for future research with the goal of delaying or treating early OA post menisicectomy with M SCs.

Intra-articular implantation of autologous bone marrow-derived mesenchymal stromal cells to treat knee osteoarthritis: a randomized, triple-blind, placebo-controlled phase 1/2 clinical trial.

Efficacy and safety of adult human bone marrow-derived, cultured, pooled, allogeneic mesenchymal stromal cells (Stempeucel®): preclinical and clinical trial in osteoarthritis of the knee joint

In the clinical study, IA administration of Stempeucel® was safe, and a trend towards improvement was seen in the 25-million-cell dose group in all subjective parameters, although this was not statistically significant when compared to placebo.

Safety, tolerability, clinical, and joint structural outcomes of a single intra-articular injection of allogeneic mesenchymal precursor cells in patients following anterior cruciate ligament reconstruction: a controlled double-blind randomised trial

Intra-articular administration of a single allogeneic MPC injection following ACL reconstruction was safe, well tolerated, and may improve symptoms and structural outcomes, suggesting that MPCs warrant further investigations as they may modulate some of the pathological processes responsible for the development of post-traumatic osteoarthritis after ACL reconstruction.

Long-Term Follow-up of Intra-articular Injection of Autologous Mesenchymal Stem Cells in Patients with Knee, Ankle, or Hip Osteoarthritis.

This study has shown that injection of MSCs in different OA affected joints is safe and therapeutically beneficial, however, further studies are needed with larger sample sizes and longer follow-up periods to confirm these findings.

Allogeneic Umbilical Cord Blood–Derived Mesenchymal Stem Cell Implantation Versus Microfracture for Large, Full-Thickness Cartilage Defects in Older Patients: A Multicenter Randomized Clinical Trial and Extended 5-Year Clinical Follow-up

In older patients with symptomatic, large, full-thickness cartilage defects with or without osteoarthritis, UCB-MSC-HA implantation resulted in improved cartilage grade at second-look arthroscopy and provided more improvement in pain and function up to 5 years compared with microfracture.

Treatment of Knee Osteoarthritis with Autologous Expanded Bone Marrow Mesenchymal Stem Cells: 50 Cases Clinical and MRI Results at One Year Follow-Up

A pilot study applying 40×10e6 autologous bone marrow expanded mesenchymal cells in 12 patients affected with knee osteoarhtritis through intra-articular infusion obtained excellent clinical and quantitative MRI outcome measures, no adverse events reported.

Additional Use of Synovial Mesenchymal Stem Cell Transplantation Following Surgical Repair of a Complex Degenerative Tear of the Medial Meniscus of the Knee: A Case Report

This first-in-human study confirmed that the combination of surgical repair and synovial MSC transplantation improved the clinical symptoms in patients with a complex degenerative tear of the medial meniscus.

Safety Studies for Use of Adipose Tissue‐Derived Mesenchymal Stromal/Stem Cells in a Rabbit Model for Osteoarthritis to Support a Phase I Clinical Trial

The data generated in this study show a favorable safety profile for AMSCs within the joint space in support of a phase I clinical trial evaluating the clinical utility of AM SCs to treat osteoarthritis.
...

References

SHOWING 1-10 OF 24 REFERENCES

Stem cell therapy in a caprine model of osteoarthritis.

Local delivery of adult mesenchymal stem cells to injured joints stimulates regeneration of meniscal tissue and retards the progressive destruction normally seen in this model of OA.

Intra‐articular Injected Synovial Stem Cells Differentiate into Meniscal Cells Directly and Promote Meniscal Regeneration Without Mobilization to Distant Organs in Rat Massive Meniscal Defect

Investigating whether intra‐articular injected synovium‐MSCs enhanced meniscal regeneration in rat massive meniscal defect found that after two to 8 weeks, the menisci regenerated much better than it did in the control group, and LacZ gene derived from MSCs could not be detected in other organs except insynovium by real‐time PCR.

The effect of the addition of adipose-derived mesenchymal stem cells to a meniscal repair in the avascular zone: an experimental study in rabbits.

Meniscal repair using bone marrow-derived mesenchymal stem cells: experimental study using green fluorescent protein transgenic rats.

Structured three‐dimensional co‐culture of mesenchymal stem cells with meniscus cells promotes meniscal phenotype without hypertrophy

Co‐culturing MC and MSC is a feasible and efficient approach to engineer meniscus tissue with enhanced ECM production without hypertrophy and the collagen fiber bundles observed in the co‐cultures are important to produce heterogenic ECM structure of menisci.

Treatment of inflammatory diseases with mesenchymal stem cells.

Human mesenchymal stem cells are rare progenitor cells present in adult bone marrow that have the capacity to differentiate into a variety of tissue types, including bone, cartilage, tendon, fat, and muscle, providing therapeutic potential for treating diseases characterized by the presence of an inflammatory component.

A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction.

Enhancement of meniscal repair in the avascular zone using mesenchymal stem cells in a porcine model.

The histological and macroscopic findings showed that the repair of meniscal tears in the avascular zone was significantly improved with MSCs, but that the mechanical properties of the healed menisci remained reduced.

Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease.

  • P. KebriaeiL. Isola J. Uberti
  • Medicine, Biology
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2009

Human mesenchymal stem cells modulate allogeneic immune cell responses.

Insight is offered into the interactions between allogeneic MSCs and immune cells and mechanisms likely involved with the in vivo MSC-mediated induction of tolerance that could be therapeutic for reduction of GVHD, rejection, and modulation of inflammation.